ORPHA:319
Skeletal Ewing sarcoma
Also known as: Osseous Ewing sarcoma
Publications
26,483
Trials
223
Interventional, condition-specific
Researchers
1,340
Distinct authors in sample
Gene link
—
Readiness
4/6
Stages with a signal
Clinical definition (Orphanet)
Ewing's sarcoma is a malignant small round cell bone tumor with strong metastatic potential.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0012817
- MeSH:D012512
- OMIM:612219
- UMLS:C0553580
- NCIT:C4817
Additional Mondo synonyms (6)
ES · Ewing sarcoma · Ewing's family localised tumour · Ewing's sarcoma · Ewing's tumor · Ewing's tumour
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
4/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
26,483 matched papers (14,806 in last 10 years) Source
- Phenotype characterisedPresent
1 HPO annotations (e.g. Ewing sarcoma) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationPresent
1 FDA designation (1 FDA orphan-indication approval) — e.g. ganitumab Source
- Interventional trialPresent
223 matched on ClinicalTrials.gov (46 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
1
Designation · 1 with FDA orphan-indication approval
- FDA ganitumabewing sarcoma · 2017-03-21 · Not FDA Approved for Orphan Indication
Sources: FDA OOPD · EMA orphan designations
Open Targets candidates
129
Drugs / clinical candidates · MONDO_0012817
- BUSULFAN·phase 3
- CYCLOPHOSPHAMIDE·phase 3
- DACTINOMYCIN·phase 3
- DINUTUXIMAB BETA·phase 3
- DOXORUBICIN·phase 3
- DOXORUBICIN HYDROCHLORIDE·phase 3
- ETOPOSIDE·phase 3
- ETOPOSIDE PHOSPHATE·phase 3
- FILGRASTIM·phase 3
- GANITUMAB·phase 3
- IFOSFAMIDE·phase 3
- IRINOTECAN·phase 3
- MELPHALAN·phase 3
- MESNA·phase 3
- MODAFINIL·phase 3
CTD chemicals (MyDisease.info)
20 associated chemicals · 8 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.
- Arsenic Trioxide · therapeutic
- Busulfan · therapeutic
- Caffeine · therapeutic
- Carboplatin · therapeutic
- Cisplatin · therapeutic
- Cyclophosphamide · therapeutic
- Dactinomycin · therapeutic
- Doxorubicin · therapeutic
- Etoposide · therapeutic
- IE protocol · therapeutic
- Ifosfamide · therapeutic
- JET protocol · therapeutic
Pathways: Hepatitis B; HTLV-I infection; Transcriptional misregulation in cancer; Viral carcinogenesis; Developmental Biology; Transcriptional regulation of white adipocyte differentiation; Activation of anterior HOX genes in hindbrain development during early embryogenesis; Activation of HOX genes during differentiation
Literature
Is anyone studying this?
26,483
26,483 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
26,483 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
14,806 in the last 10 years · low confidence
Phrase hits: 26,483 · MeSH hits: 0
Who's working on it?
1,340
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Gambarotti M5 papers · 2026
Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Papers in Europe PMC - 02Aiba H3 papers · 2026
Department of Orthopedic Surgery, Nagoya City University, Nagoya, Aichi, 467-8601, Japan.
Papers in Europe PMC - 03Allali N3 papers · 2026
Department of Radiology, Rabat Children's Hospital, University Mohammed V of Rabat, Morocco.
Papers in Europe PMC - 04Chat L3 papers · 2026
Department of Radiology, Rabat Children's Hospital, University Mohammed V of Rabat, Morocco.
Papers in Europe PMC - 05Dirksen U3 papers · 2026
Pediatrics III, University Hospital Essen, German Cancer Consortium (DKTK) Site Essen, Cancer Research Center (NCT) Cologne-Essen, Hufelandstraße 55, 45147 Essen, Germany.
Papers in Europe PMC - 06Donati DM3 papers · 2026
Clinica Ortopedica e Traumatologica III a Prevalente Indirizzo Oncologico, IRCCS Istituto Ortopedico Rizzoli, Via Giulio Cesare Pupilli1, 40136 Bologna, Italy.
Papers in Europe PMC - 07Errani C3 papers · 2026
Department of Orthopedic Oncology, IRCCS Istituto Ortopedico Rizzoli, 40136, Bologna, Italy.
Papers in Europe PMC - 08Kumar M3 papers · 2025
Urology, Arrowe Park Hospital, Wirral University Teaching Hospital NHS Foundation Trust, Wirral, GBR.
Papers in Europe PMC - 09Spinnato P3 papers · 2026
Diagnostic and Interventional Radiology, IRCCS Istituto Ortopedico Rizzoli, 40136, Bologna, Italy.
Papers in Europe PMC - 10
Clinical research
Is a treatment being tested?
223
interventional trials for this specific condition
223 interventional trials matched this specific condition name; 46 currently recruiting in our sample. 1,434 trials are registered for sarcoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
223 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 99.4th percentile).
low confidence · 99.4th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
223 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06839703·NOT YET RECRUITING·International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing Sarkoma
Not reviewed·Conditions: High-risk GD2-Positive Ewing Sarcoma·Matched via name phrase
- NCT06395103·RECRUITING·Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Not reviewed·Conditions: B-cell Acute Lymphoblastic Leukemia · Diffuse Large B-cell Lymphoma · Burkitt Lymphoma · Neuroblastoma·Matched via name phrase
- NCT06926283·RECRUITING·A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
Not reviewed·Conditions: Prostate Cancer · Other Solid Tumors · Ewing Sarcoma·Matched via name phrase
- NCT03715933·RECRUITING·Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Not reviewed·Conditions: Ewing Sarcoma · Colorectal Adenocarcinoma·Matched via name phrase
- NCT07695311·NOT YET RECRUITING·EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT
Not reviewed·Conditions: Ewing Sarcoma · Desmoplastic Small Round Cell Tumor·Matched via name phrase
- NCT04851119·RECRUITING·Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Not reviewed·Conditions: Colorectal Carcinoma · Endometrial Carcinoma · Melanoma · Neuroblastoma·Matched via name phrase
- NCT06796543·RECRUITING·Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
Not reviewed·Conditions: Metastatic Sarcoma · Radiation Therapy Patient · Ewing Sarcoma · Rhabdomyosarcoma·Matched via name phrase
- NCT04055220·RECRUITING·Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
Not reviewed·Conditions: Bone Sarcoma · Osteosarcoma · Ewing Sarcoma · Chondrosarcoma·Matched via name phrase
- NCT07172958·RECRUITING·Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
Not reviewed·Conditions: Rhabdomyosarcoma · Ewing Sarcoma · Neuroblastoma · Wilms Tumor·Matched via name phrase
- NCT06892678·RECRUITING·DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma
Not reviewed·Conditions: Osteosarcoma Recurrent · Ewing's Tumor Recurrent·Matched via name phrase
- NCT07516353·NOT YET RECRUITING·my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults
Not reviewed·Conditions: Sarcoma · Osteosarcoma · Ewing Sarcoma · Rhabdomyosarcoma·Matched via name phrase
- NCT04433221·RECRUITING·Combination Immunotherapy Targeting Sarcomas
Not reviewed·Conditions: Sarcoma · Osteoid Sarcoma · Ewing Sarcoma·Matched via name phrase
- NCT06340204·RECRUITING·Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma
Not reviewed·Conditions: Ewing Sarcoma·Matched via name phrase
- NCT06699472·RECRUITING·A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib
Not reviewed·Conditions: Ewing Sarcoma · Myelosuppression·Matched via name phrase
- NCT03356782·RECRUITING·Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas
Not reviewed·Conditions: Sarcoma · Osteoid Sarcoma · Ewing Sarcoma·Matched via name phrase
Broader category: sarcoma
1,434
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07359053·RECRUITING·MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced Sarcoma
Not reviewed·Conditions: Sarcoma·Matched via name phrase
- NCT06805773·RECRUITING·Evaluating the Use of Educational Videos in Newly Diagnosed Patients in a Medical Oncology Sarcoma Clinic
Not reviewed·Conditions: Sarcoma·Matched via name phrase
- NCT07460986·NOT YET RECRUITING·A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA
Not reviewed·Conditions: Sarcoma of Soft Tissue·Matched via name phrase
- NCT07134192·RECRUITING·Fluorescence-Guided Optimization of Sarcoma Margins
Not reviewed·Conditions: Soft Tissue Sarcoma of the Trunk and Extremities · Sarcoma·Matched via name phrase
- NCT01659203·RECRUITING·Proton or Photon RT for Retroperitoneal Sarcomas
Not reviewed·Conditions: Retroperitoneal Sarcoma·Matched via name phrase
- NCT07032285·RECRUITING·Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas
Not reviewed·Conditions: Soft Tissue Sarcoma (STS)·Matched via name phrase
- NCT07308886·RECRUITING·Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
Not reviewed·Conditions: Kaposi Sarcoma·Matched via name phrase
- NCT06789666·RECRUITING·Digital Art Therapy for Young Cancer Survivors
Not reviewed·Conditions: Cancer · Pediatric Cancer · Pediatric Malignancies · Pediatric Sarcoma of Soft Tissue·Matched via name phrase
- NCT07052383·RECRUITING·Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas
Not reviewed·Conditions: Osteosarcoma · Soft Tissue Sarcoma·Matched via name phrase
- NCT06066138·RECRUITING·A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Not reviewed·Conditions: Locally Advanced Alveolar Soft Part Sarcoma · Metastatic Alveolar Soft Part Sarcoma · Locally Advanced Non Small Cell Lung Cancer · Metastatic Non Small Cell Lung Cancer·Matched via name phrase
- NCT06498648·RECRUITING·Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
Not reviewed·Conditions: Advanced Dedifferentiated Liposarcoma · Advanced Leiomyosarcoma · Advanced Soft Tissue Sarcoma · Metastatic Dedifferentiated Liposarcoma·Matched via name phrase
- NCT06371768·RECRUITING·Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
Not reviewed·Conditions: Cancer · Breast Cancer · Colorectal Cancer · Sarcoma·Matched via name phrase
- NCT04698785·RECRUITING·Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients
Not reviewed·Conditions: Bone Sarcoma · Osteosarcoma·Matched via name phrase
- NCT03054792·ENROLLING BY INVITATION·Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas
Not reviewed·Conditions: Rhabdomyosarcoma · Non-Rhabdo. Soft Tissue Sarcoma·Matched via name phrase
- NCT03422198·RECRUITING·Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
Not reviewed·Conditions: Endometrial Clear Cell Adenocarcinoma · Endometrial Endometrioid Adenocarcinoma · Endometrial Serous Adenocarcinoma · Stage I Uterine Corpus Cancer·Matched via name phrase
Observational and natural-history studies
36 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07620431·NOT YET RECRUITING·Neoadjuvant Radiotherapy and Surgery for High-Risk Localized Ewing Sarcoma
Not reviewed·Conditions: Ewing Sarcoma · Bone Neoplasms·Matched via name phrase
- NCT07141862·RECRUITING·Fertility Preservation in Children With Solid Tumors: Detection of Residual Disease by a Sensitive Method
Not reviewed·Conditions: Neuroblastoma · Ewing Sarcoma·Matched via name phrase
- NCT05062707·RECRUITING·Early Ageing During Therapy in AYA Cancer Patients
Not reviewed·Conditions: Cancer · Leukemia · Hodgkin Lymphoma · Testicular Cancer·Matched via name phrase
- NCT06935864·RECRUITING·Tissue Expression of Krüppel-Like Factors 4 and 7 in Bone Tumors
Not reviewed·Conditions: Osteosarcoma in Children · Ewing Sarcoma of Bone or Soft Tissue·Matched via name phrase
- NCT03442465·RECRUITING·Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas
Not reviewed·Conditions: Bone Sarcoma · Osteosarcoma · Chondrosarcoma · Ewing's Sarcoma·Matched via name phrase
- NCT04845893·RECRUITING·Observational Study on Skeletal Ewing's Sarcoma
Not reviewed·Conditions: Ewing Sarcoma of Bone·Matched via name phrase
- NCT05779670·RECRUITING·Adherence to a Personalized Home Exercise Program in Patients With Bone Tumor Undergoing Lower Extremity Salvage Surgery
Not reviewed·Conditions: Osteosarcoma · Ewing Sarcoma · Chondrosarcoma · Bone Tumor·Matched via name phrase
- NCT07725783·RECRUITING·Prospective Evaluation of Dynamic Serum ProGRP for Treatment Response Monitoring in Ewing Sarcoma
Not reviewed·Conditions: Ewing Sarcoma·Matched via name phrase
- NCT06243588·RECRUITING·Identification of Prognostic Factors and Role of Radiotherapy in Patients With Ewing Sarcoma
Not reviewed·Conditions: Ewing Sarcoma·Matched via name phrase
- NCT05033288·RECRUITING·Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone
Not reviewed·Conditions: Bone Sarcoma · Chondrosarcoma · Chordoma · Ewing Sarcoma of Bone·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 31 · after dedupe 31 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 31 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (31)
- ctis·2025-521497-34-00·Authorised, ongoing·Long-term follow-up of patients treated with GD2IL18CART
skipped — LLM skipped (--skip-llm)
- ctis·2024-511989-36-00·Authorised, ongoing·INTER-EWING-1: International Clinical Research Programme to Improve Outcomes in Newly Diagnosed Ewing Sarcoma – Trial 1
skipped — LLM skipped (--skip-llm)
- ctis·2024-515245-42-00·Authorised, recruiting·International open-label phase I dose escalation study of dinutuximab beta in combination with vincristine/doxorubicin/cyclophosphamide and ifosfamide/etoposide in pediatric, adolescent, and adult patients with GD2-positive Ewing sarcoma
skipped — LLM skipped (--skip-llm)
- ctis·2024-518912-37-01·Authorised·Phase II Prospective Multicenter Study of High-Dose Treosulfan/Melphalan as Consolidation Treatment in Newly Diagnosed High-Risk and Very High-Risk Ewing Sarcoma.
skipped — LLM skipped (--skip-llm)
- ctis·2024-516078-31-00·Authorised, ongoing·rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma
skipped — LLM skipped (--skip-llm)
- ctis·2023-509496-16-00·Authorised, ongoing·PEMBROCABOSARC : COMBINATION OF PEMBROLIZUMAB AND CABOZANTINIB IN PATIENTS WITH ADVANCED SARCOMAS
skipped — LLM skipped (--skip-llm)
- ctis·2024-511337-35-00·Authorised, recruiting·Prospective phase I/II trial of an individualized peptide vaccine in
pediatric and AYA patients with metastasized fusion-driven
sarcomas following standard treatment
skipped — LLM skipped (--skip-llm)
- ctis·2024-511975-14-00·Cancelled·A5481092: PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS
skipped — LLM skipped (--skip-llm)
- ctis·2024-513455-33-00·Expired·REGOBONE_A Randomized Phase II, placebo-controlled, multicenter study evaluating efficacy and safety of regorafenib in patients with metastatic bone sarcomas
skipped — LLM skipped (--skip-llm)
- ctis·2024-514441-11-00·Authorised, ongoing·To evaluate the efficacy and safety of naxitamab in patients with refractory Ewing's sarcoma.
skipped — LLM skipped (--skip-llm)
- ctis·2024-512135-80-00·Cancelled·An Open-Label, Multicenter Phase 2 Basket Study to Evaluate the Antitumor Activity and Safety of Lenvatinib in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Malignancies
skipped — LLM skipped (--skip-llm)
- ctis·2023-508139-29-00·Authorised, ongoing·An Open-Label, Multicenter, First-in-Human, Phase 1 Dose Escalation and Multicohort Expansion Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors, Including Sarcomas.
skipped — LLM skipped (--skip-llm)
- ctis·2023-507178-41-00·Authorised, ongoing·LIGHTBEAM-U01-Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants with Hematologic Malignancies or Solid Tumors.
skipped — LLM skipped (--skip-llm)
- ctis·2022-501725-21-00·Authorised, ongoing·A phase I safety, dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers
skipped — LLM skipped (--skip-llm)
- ctis·2023-503322-39-00·Authorised, recruiting·Phase Ib study of the combination of regorafenib with conventional chemotherapy for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma - REGO-INTER-EWING1
skipped — LLM skipped (--skip-llm)
- ctis·2022-501180-40-00·Authorised, ongoing·International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN07742377·No longer recruiting·Gemcitabine and Docetaxel versus Doxorubicin as first line treatment in previously untreated advanced unresectable or metastatic soft tissue Sarcomas
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15121868·No longer recruiting·Study for rhabdomyosarcoma and other malignant soft tissue tumours of childhood
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN75533638·Recruiting·CAR-T cells for children, teenagers and young adults with sarcoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17938906·Recruiting·International clinical research programme to improve outcomes in newly diagnosed Ewing sarcoma – Trial 1
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN94236001·No longer recruiting·LINES: Eurosarc trial of LINsitinib in advanced Ewing Sarcoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN52616678·No longer recruiting·Pharmacokinetic variation and toxicity in Ewing's sarcoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN36453794·Recruiting·Chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN92192408·No longer recruiting·Euro Ewing 2012
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN57509500·No longer recruiting·Study to assess the age-dependency in the clearance of doxorubicin in children with leukaemia and solid tumours
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Skeletal Ewing sarcoma — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Skeletal Ewing sarcoma" OR "Osseous Ewing sarcoma" OR "Ewing sarcoma" OR "Ewing's family localised tumour" OR "Ewing's sarcoma" OR "Ewing's tumor" OR "Ewing's tumour"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Skeletal Ewing sarcoma" OR "Osseous Ewing sarcoma" OR "Ewing sarcoma" OR "Ewing's family localised tumour" OR "Ewing's sarcoma" OR "Ewing's tumor" OR "Ewing's tumour"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 223 interventional · 36 observational · 2 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"sarcoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: ES
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (26483) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T13:23:12.423Z
